← Leaderboards
Richard N Kolesnick
Sloan-Kettering Inst Can Research
$17,601,323
Attributed
$17,601,323
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,601,323 · 9
By mechanism
R01$13,006,837 · 5
U01$3,734,264 · 2
R21$860,222 · 2
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Scott W Lowe$63,222,126
- Arvin Dar$9,617,218
Others in their field
Top investigators on “Ceramides”
- Yusuf Awni Hannun · Medical University Of South Carolina$31,236,776
- Besim Ogretmen · Medical University Of South Carolina$16,800,540
- Scott A Summers · Colorado State University-Fort Collins$15,094,141
- Pin-Lan Li · Medical College Of Wisconsin$14,567,134
- Susan J Sumner · Research Triangle Institute$13,509,958
- Sarah Spiegel · Virginia Commonwealth University$13,299,666
Research focus
CeramidesApoptosisMediatingApoptoticResponseTumorDoseEndothelial CellsSignal TransductionAcid SphingomyelinaseEndotheliumSphingomyelinsDesignNeoplastic CellCell MembraneMemorial Sloan-Kettering Cancer CenterRadiationCellsResistanceIonizing RadiationBaseCell DeathIn VivoRadiation Therapy
Grant awards (46)
Anti-ceramide Ab Preserves Intestinal Stem Cells and Prevents GI-ARS and GI-DEARE$597,518
U01 · FY2025 · AI · contact PI
Ceramide-Rich Platforms Functionalize Gemcitabine Uptake$404,888
R01 · FY2025 · CA · contact PI
Ceramide-Rich Platforms Functionalize Gemcitabine Uptake$384,644
R01 · FY2024 · CA · contact PI
Ceramide-Rich Platforms Functionalize Gemcitabine Uptake$396,790
R01 · FY2023 · CA · contact PI
Ceramide-Rich Platforms Functionalize Gemcitabine Uptake$396,790
R01 · FY2022 · CA · contact PI
Patient-derived organoids reveal rectal cancers develop radiosensitivity$243,278
R21 · FY2022 · CA · contact PI
Dissecting anti-ceramide scFv vascular mitigation of the Radiation GI Syndrome$583,790
U01 · FY2021 · AI · contact PI
Ceramide-Rich Platforms Functionalize Gemcitabine Uptake$404,888
R01 · FY2021 · CA · contact PI
Patient-derived organoids reveal rectal cancers develop radiosensitivity$206,869
R21 · FY2021 · CA · contact PI
Dissecting anti-ceramide scFv vascular mitigation of the Radiation GI Syndrome$592,872
U01 · FY2020 · AI · contact PI
C16-Ceramide Nano-Liposomes Reverse Multi-Drug Resistance$410,835
R01 · FY2020 · CA · contact PI
Dissecting anti-ceramide scFv vascular mitigation of the Radiation GI Syndrome$761,714
U01 · FY2019 · AI · contact PI
C16-Ceramide Nano-Liposomes Reverse Multi-Drug Resistance$398,509
R01 · FY2019 · CA · contact PI
Dissecting anti-ceramide scFv vascular mitigation of the Radiation GI Syndrome$593,570
U01 · FY2018 · AI · contact PI
C16-Ceramide Nano-Liposomes Reverse Multi-Drug Resistance$392,078
R01 · FY2018 · CA · contact PI
Dissecting anti-ceramide scFv vascular mitigation of the Radiation GI Syndrome$604,800
U01 · FY2017 · AI · contact PI
C16-Ceramide Nano-Liposomes Reverse Multi-Drug Resistance$392,078
R01 · FY2017 · CA · contact PI
Sphingolipid-Based Anti-Angiogenic Chemosensitization$223,677
R21 · FY2017 · CA · contact PI
C16-Ceramide Nano-Liposomes Reverse Multi-Drug Resistance$392,078
R01 · FY2016 · CA · contact PI
Re-setting the Endothelial Ceramide Rheostat$379,518
R01 · FY2016 · CA · contact PI
Sphingolipid-Based Anti-Angiogenic Chemosensitization$186,398
R21 · FY2016 · CA · contact PI
Re-setting the Endothelial Ceramide Rheostat$379,518
R01 · FY2015 · CA · contact PI
Re-setting the Endothelial Ceramide Rheostat$368,132
R01 · FY2014 · CA · contact PI
Re-setting the Endothelial Ceramide Rheostat$356,747
R01 · FY2013 · CA · contact PI
Re-setting the Endothelial Ceramide Rheostat$379,518
R01 · FY2012 · CA · contact PI
Targeting KSR to Treat Pancreatic Cancer$324,495
R01 · FY2010 · CA · contact PI
Modulation of Ceramide Induced Apoptosis in Vivo$389,561
R01 · FY2009 · CA · contact PI
Targeting KSR to Treat Pancreatic Cancer$324,495
R01 · FY2009 · CA · contact PI
Modulation of Ceramide Induced Apoptosis in Vivo$389,561
R01 · FY2008 · CA · contact PI
Targeting KSR to Treat Pancreatic Cancer$324,495
R01 · FY2008 · CA · contact PI
Modulation of Ceramide Induced Apoptosis in Vivo$389,561
R01 · FY2007 · CA · contact PI
Targeting KSR to Treat Pancreatic Cancer$324,495
R01 · FY2007 · CA · contact PI
Modulation of Ceramide Induced Apoptosis in Vivo$367,799
R01 · FY2006 · CA · contact PI
Targeting KSR to Treat Pancreatic Cancer$336,747
R01 · FY2006 · CA · contact PI
Modulation of Ceramide Induced Apoptosis in Vivo$376,650
R01 · FY2005 · CA
Mechanisms of KSR signaling$304,403
R01 · FY2005 · CA
MODULATION OF CERAMIDE INDUCED APOPTOSIS IN VIVO$365,175
R01 · FY2004 · CA
Mechanisms of KSR signaling$304,403
R01 · FY2004 · CA
MODULATION OF CERAMIDE INDUCED APOPTOSIS IN VIVO$365,175
R01 · FY2003 · CA
Mechanisms of KSR signaling$304,403
R01 · FY2003 · CA
MODULATION OF CERAMIDE INDUCED APOPTOSIS IN VIVO$365,175
R01 · FY2002 · CA
Mechanisms of KSR signaling$304,403
R01 · FY2002 · CA
MODULATION OF CERAMIDE INDUCED APOPTOSIS IN VIVO$365,175
R01 · FY2001 · CA
Mechanisms of KSR signaling$305,429
R01 · FY2001 · CA
MODULATION OF CERAMIDE INDUCED APOPTOSIS IN VIVO$365,175
R01 · FY2000 · CA
IDENTIFICATION/REGULATION OF CERAMIDE ACTIVATED PROTEINS$273,051
R01 · FY2000 · CA